Literature DB >> 7983735

Negative regulation of the bovine papillomavirus E5, E6, and E7 oncogenes by the viral E1 and E2 genes.

S B Vande Pol1, P M Howley.   

Abstract

Papillomaviruses induce benign squamous epithelial lesions that infrequently are associated with uncontrolled growth or malignant conversion. The virus-encoded oncogenes are clearly under negative regulation since papillomaviruses can latently infect cells and since different levels of viral oncogene expression are seen within the layers of differentiating infected epitheliomas. We used bovine papillomavirus type 1 (BPV-1) to investigate the mechanisms involved in the negative regulation of transformation. We found that the following two distinct and interacting mechanisms negatively regulate BPV-1 transformation effected by virally encoded trans-acting factors: (i) E2 repressors suppress transformation by the E6 and E7 oncogenes, and (ii) E1 and the E2 transactivator suppress transformation by the E6, E7, and E5 oncogenes. These systems interact in that the E2 repressors function to relieve the transformation suppression effected by the E1 and E2 transactivator genes. A BPV-1 mutant that lacked E2 repressors and E1 had greatly augmented transformation capacity. Analysis of this mutant revealed that the enhanced transformation was due to expression of the E6 and E7 genes in the absence of E5, revealing a previously unappreciated potency and synergy for the BPV-1 E6 and E7 oncogenes.

Entities:  

Mesh:

Year:  1995        PMID: 7983735      PMCID: PMC188587          DOI: 10.1128/JVI.69.1.395-402.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Characterization of rare human papillomavirus type 11 mRNAs coding for regulatory and structural proteins, using the polymerase chain reaction.

Authors:  M O Rotenberg; L T Chow; T R Broker
Journal:  Virology       Date:  1989-10       Impact factor: 3.616

2.  The 68-kilodalton E1 protein of bovine papillomavirus is a DNA binding phosphoprotein which associates with the E2 transcriptional activator in vitro.

Authors:  I L Blitz; L A Laimins
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

3.  Bovine papillomavirus E2 repressor mutant displays a high-copy-number phenotype and enhanced transforming activity.

Authors:  D J Riese; J Settleman; K Neary; D DiMaio
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

4.  The E6/E7 promoter of human papillomavirus type 16 is activated in the absence of E2 proteins by a sequence-aberrant Sp1 distal element.

Authors:  B Gloss; H U Bernard
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

5.  Colposcopy, punch biopsy, in situ DNA hybridization, and the polymerase chain reaction in searching for genital human papillomavirus (HPV) infections in women with normal PAP smears.

Authors:  S Syrjänen; J Saastamoinen; F J Chang; H X Ji; K Syrjänen
Journal:  J Med Virol       Date:  1990-08       Impact factor: 2.327

6.  Bovine papillomavirus type 1 encodes two forms of a transcriptional repressor: structural and functional analysis of new viral cDNAs.

Authors:  J Choe; P Vaillancourt; A Stenlund; M Botchan
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

7.  Phenotypic analysis of bovine papillomavirus type 1 E2 repressor mutants.

Authors:  P F Lambert; B C Monk; P M Howley
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

8.  Infectious cycle of human papillomavirus type 11 in human foreskin xenografts in nude mice.

Authors:  M H Stoler; A Whitbeck; S M Wolinsky; T R Broker; L T Chow; M K Howett; J W Kreider
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

9.  Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen.

Authors:  L P Chen; E K Thomas; S L Hu; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

10.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

Authors:  L Chen; S Ashe; W A Brady; I Hellström; K E Hellström; J A Ledbetter; P McGowan; P S Linsley
Journal:  Cell       Date:  1992-12-24       Impact factor: 41.582

View more
  14 in total

1.  Inhibition of E2 binding to Brd4 enhances viral genome loss and phenotypic reversion of bovine papillomavirus-transformed cells.

Authors:  Jianxin You; Michal-Ruth Schweiger; Peter M Howley
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

2.  p53 protein is a suppressor of papillomavirus DNA amplificational replication.

Authors:  D Lepik; I Ilves; A Kristjuhan; T Maimets; M Ustav
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

Review 3.  Vectors for cancer gene therapy.

Authors:  J Zhang; S J Russell
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

4.  Transformation by bovine papillomavirus type 1 E6 is independent of transcriptional activation by E6.

Authors:  R Ned; S Allen; S Vande Pol
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  Identification of a second transforming function in bovine papillomavirus type 1 E6 and the role of E6 interactions with paxillin, E6BP, and E6AP.

Authors:  K Das; J Bohl; S B Vande Pol
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  Cooperative transformation and coexpression of bovine papillomavirus type 1 E5 and E7 proteins.

Authors:  J Bohl; B Hull; S B Vande Pol
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  A papillomavirus E2 phosphorylation mutant exhibits normal transient replication and transcription but is defective in transformation and plasmid retention.

Authors:  C W Lehman; D S King; M R Botchan
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

8.  Human TATA binding protein inhibits human papillomavirus type 11 DNA replication by antagonizing E1-E2 protein complex formation on the viral origin of replication.

Authors:  Kelly A Hartley; Kenneth A Alexander
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600.

Authors:  Kyung-Won Huh; Joseph DeMasi; Hidesato Ogawa; Yoshihiro Nakatani; Peter M Howley; Karl Münger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-01       Impact factor: 11.205

10.  Targeted mutagenesis of the human papillomavirus type 16 E2 transactivation domain reveals separable transcriptional activation and DNA replication functions.

Authors:  H Sakai; T Yasugi; J D Benson; J J Dowhanick; P M Howley
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.